Ensign Peak Advisors
AGIO icon

Ensign Peak Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Ensign Peak Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
297,630
+291,060
+4,430% +$8.83M 0.02% 420
2026
Q1 		$222K Hold
6,570
– – ﹤0.01% 1267
2025
Q4 		$179K Sell
6,570
-6,050
-48% -$212K ﹤0.01% 1360
2025
Q3 		$507K Sell
12,620
-12,350
-49% -$465K ﹤0.01% 1380
2025
Q2 		$831K Sell
24,970
-6,950
-22% -$211K ﹤0.01% 1353
2025
Q1 		$935K Hold
31,920
– – ﹤0.01% 1293
2024
Q4 		$1.05M Hold
31,920
– – ﹤0.01% 1294
2024
Q3 		$1.42M Hold
31,920
– – ﹤0.01% 1120
2024
Q2 		$1.38M Hold
31,920
– – ﹤0.01% 1082
2024
Q1 		$933K Sell
31,920
-1,610
-5% -$43.1K ﹤0.01% 1376
2023
Q4 		$747K Hold
33,530
– – ﹤0.01% 1535
2023
Q3 		$830K Hold
33,530
– – ﹤0.01% 1340
2023
Q2 		$950K Hold
33,530
– – ﹤0.01% 1305
2023
Q1 		$770K Hold
33,530
– – ﹤0.01% 1444
2022
Q4 		$942K Buy
33,530
+21,100
+170% +$595K ﹤0.01% 1209
2022
Q3 		$352K Buy
12,430
+250
+2% +$6.71K ﹤0.01% 1633
2022
Q2 		$270K Hold
12,180
– – ﹤0.01% 1710
2022
Q1 		$355K Hold
12,180
– – ﹤0.01% 1692
2021
Q4 		$400K Buy
+12,180
New +$490K ﹤0.01% 1702

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Ensign Peak Advisors's AGIO Position: Q2 2026 in Review

Ensign Peak Advisors increased its Agios Pharmaceuticals (AGIO) stake by 4,430% in Q2 2026, buying an estimated $8.83M and bringing the position to 297,630 shares worth $11M. The position accounts for 0.02% of the portfolio, ranked #420.

Ensign Peak Advisors first reported a position in AGIO in Q4 2021 and has held it in 19 quarters since. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Ensign Peak Advisors held 297,630 shares of Agios Pharmaceuticals worth $11M as of Q2 2026.
  • Ensign Peak Advisors bought 291,060 Agios Pharmaceuticals shares in Q2 2026, an estimated $8.83M.
  • Agios Pharmaceuticals made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #420 holding.
  • Ensign Peak Advisors first reported a position in Agios Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.